Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia,
bipolar disorders and other psychotic disorders. However, they might cause metabolic …

Abstract Treatment resistant schizophrenia (TRS) refers to the significant proportion of
schizophrenia patients who continue to have symptoms and poor outcomes despite …

The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug
clozapine has been a revolutionary pharmacological step for treating psychotic patients as …

Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

The variability in the response to antipsychotic medication in schizophrenia may reflect
between-patient differences in neurobiology. Recent cross-sectional neuroimaging studies …

Abstract Background Real-World Data (RWD) studies provide important insights in disease
epidemiology, in real clinical populations, with long follow-up periods. The aim of the …

Background It has been hypothesized that dopamine function in schizophrenia exhibits
heterogeneity in excess of that seen in the general population. However, no previous study …

Résumé Objectifs Le vieillissement accéléré du cerveau, c'est-à-dire les modifications
structurelles du cerveau liées à l'âge et apparaissant plus tôt que prévu par rapport à l'âge …

The clinical presentation of schizophrenia encompasses symptoms divided into three
dimensions: positive, negative, and cognitive. Negative symptoms (NS), in particular, have a …